Clinical Trials Logo

Muscle Invasive Bladder Cancer clinical trials

View clinical trials related to Muscle Invasive Bladder Cancer.

Filter by:

NCT ID: NCT04099589 Recruiting - Clinical trials for Muscle-invasive Bladder Cancer

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder cancer, especially chemotherapy combined with immunotherapy, however, available data of retrospective studies showed this neoadjuvant treatment model might benefit patients. So This prospective Phase II clinical trial was designed to explore the efficacy of chemotherapy combined with PD-1 inhibitor as neoadjuvant therapy in upper urinary and muscle-invasive bladder urothelial carcinoma, then to improve the rate of complete pathological remission, survival and provide medical evidence.

NCT ID: NCT04047693 Recruiting - Clinical trials for Urothelial Carcinoma

Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

The objective is to investigate the efficacy and safety of four cycles of ddMVAC with G-CSF support in patients with MIBC and locally advanced UC

NCT ID: NCT03747419 Recruiting - Bladder Cancer Clinical Trials

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Start date: December 13, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying the effects of adding a certain type of immunotherapy to standard bladder-directed radiation as a treatment for muscle-invasive urothelial carcinoma of the bladder. The drug in this study is: Avelumab (also known as BAVENCIO®)

NCT ID: NCT02648100 Recruiting - Clinical trials for Muscle Invasive Bladder Cancer

Basal Like Bladder Cancer : Signature and Therapeutic

DIATRIBBE
Start date: March 2014
Phase: N/A
Study type: Observational

Muscle invasive (MIBC) and/or metastatic bladder cancer is associated with poor prognosis and no target therapies for this pathology are currently validated. By 40 gene expression signature realized on frozen samples, we have previously identified an aggressive sub-class of MIBC, called basal. This sub-class (20% of MIBC) showed strong EGFR dependence in vitro and in vivo (Rebouissou et al. Science Translational Medicine 2014). This observation suggests a possible response to EGFR targeted therapy in patients of this subgroup. Our aim is to establish a standard diagnostic tool to differentiate the basal subtype of bladder cancer and evaluate the effect of anti-EGFR therapy, by analyzing previous clinical trial (GETUG19) and preclinical models, which compare the classical chemotherapy to anti-EGFR associated chemotherapy.